Biotech Strategy Blog

Commentary on Science, Innovation & New Products

Posts tagged ‘EAU 2012 Congress’

The Mannogram – how imaging may revolutionize prostate cancer diagnosis

By on March 8, 2012

Slide011 300x210 The Mannogram – how imaging may revolutionize prostate cancer diagnosis“The Mannogram – Yes we scan” Jelle Barentsz, Professor of Radiology at Radbound University, Nijmegen, The Netherlands told the assembled media at the recent European Association of Urology (EAU) annual Congress in Paris.

Professor Barentsz described how advances in magnetic resonance imaging (MRI), and in particular multi-parametric MRI (Mp-MRI) offer the potential for the improved detection and characterization of prostate cancer.

In the same way there is a mammogram that women use for breast cancer screening, Professor Barentsz raised the possibility that using magnetic resonance imaging, men could have a mannogram to screen and diagnose prostate cancer.

This is a preview of The Mannogram – how imaging may revolutionize prostate cancer diagnosis. Read the full post

Leave a comment

PIVOT data continues to show no survival benefit for prostatectomy over watchful waiting in men with low to medium risk early prostate cancer

By on March 6, 2012

EAU 2012 Wilt PIVOT Title Slide 300x168 PIVOT data continues to show no survival benefit for prostatectomy over watchful waiting in men with low to medium risk early prostate cancer Timothy J. Wilt MD, MPH presented an update on the VA, NCI, AHRQ Prostate cancer Intervention Versus Observation Trial (PIVOT) on the final day of the 2012 European Association of Urology (EAU) Congress in Paris.

I previously wrote on this blog about the PIVOT data presented by Professor Wilt in the plenary session at the 2011 American Urological Association Annual meeting.

The PIVOT trial objective according to Dr Wilt, was to answer the following question:

Among men with clinically localized prostate cancer detected during the early PSA era, does the intent to treat with radical prostectomy reduce all-cause & prostate cancer mortality compared to observation?

This is a preview of PIVOT data continues to show no survival benefit for prostatectomy over watchful waiting in men with low to medium risk early prostate cancer. Read the full post

Leave a comment

Update on Orteronel TAK-700 from EAU 2012 Paris #EAU12

By on February 26, 2012

There are no major presentations of phase III clinical trial data at the European Association of Urology (EAU) Congress in Paris this weekend, but interesting clinical and scientific data is still being presented.

If you want to understand the competitive dynamics of the prostate cancer market and the market opportunity with urologists, then you need to be at meetings such as EAU in Europe and AUA in the United States.

EAU 2012 Prostate Cancer Poster Session1 225x300 Update on Orteronel TAK 700 from EAU 2012 Paris #EAU12There was a lot of interest in yesterday’s advanced prostate cancer poster session at EAU 2012.

This is a preview of Update on Orteronel TAK-700 from EAU 2012 Paris #EAU12. Read the full post

Leave a comment